Year of taking risky blood thinners may be unnecessary after stent surgery

September 20, 2012 by Maureen Salamon, Healthday Reporter
Year of taking risky blood thinners may be unnecessary after stent surgery
Studies suggest it might be safe to stop double anti-platelet therapy sooner.

(HealthDay)—A full year of aggressive anti-clotting therapy—which can lead to heavy bleeding—may not be needed after surgery to implant a drug-coated cardiac stent, two new studies suggest.

Standard treatment for patients receiving so-called drug-eluting , which prop open after angioplasty, typically entails 12 months of double anti-platelet therapy consisting of aspirin and prescription . Korean and Spanish research indicates, however, that patients who discontinue such risky therapy after several months suffer no more ill effects than those treated for a year.

"The interesting thing is, we went through a period of time so panicked about anti-platelet therapy interruptions and the effect they might have," said Dr. Kirk Garratt, director of clinical research at Lenox Hill Heart and Vascular Institute of New York City, who was not involved in the studies. "But over the last few years, a series of reports and clinical trials say the same thing—that we probably don't need to be as worked up about it as we used to be."

The studies are scheduled for publication Sept. 21 in the Journal of the American College of Cardiology.

Cardiac stents— tubes that prevent from re-closing—are implanted in more than 500,000 Americans each year, according to the U.S. . Some stents are coated with slowly released medication to prevent the growth of in the artery lining.

Prescription blood thinners used in double anti-platelet therapy, such as () and warfarin (Coumadin), are tricky to dose properly and can lead to life-threatening bleeding complications.

The Korean study split more than 2,100 patients, all of whom underwent stent surgery after angina (chest pain) or a heart attack, into groups treated with either three months of double anti-platelet therapy or the standard 12-month course. After a year, just less than 5 percent of both groups had suffered complications such as death, bleeding, heart attack or clotting near the stent.

The Spanish study addressed interruptions in double anti-platelet therapy due to noncompliance, surgery or other medical decisions in a group of 1,600 patients. Most of the 10.6 percent of patients who discontinued the therapy did so temporarily, but this practice didn't translate into more serious consequences compared to those whose therapy was not interrupted.

"The big takeaway is that neither of these studies fundamentally change the way I think about these therapies for my patients," Garratt said. "But the Spanish study increases my confidence in the way I'm managing these patients."

But Dr. Christopher Cove, associate professor of medicine and assistant director of the cardiac catheterization lab at University of Rochester Medical Center in New York, cautioned it would be a mistake to think it's safe to stop double anti-platelet therapy based on the new research. Larger studies are needed, he added.

"We know that [double anti-platelet therapy] is beneficial as compared to aspirin alone in large groups of patients, and that there's a high risk of bleeding with it," Cove said. "What we really need to know is, if we have to stop double anti-platelet therapy, when is the safe time to do that."

Explore further: 3-drug regimen equal to double-dose 2-drug approach in preventing clots after angioplasty

More information: The American Heart Association has more about angioplasty and stents.

Related Stories

3-drug regimen equal to double-dose 2-drug approach in preventing clots after angioplasty

March 26, 2012
In a comparison of drugs to prevent blood clots after angioplasty, a three-drug regimen favored in Asia to increase anti-clotting effect was found to be as safe and effective as a double-dose two-drug treatment commonly used ...

New class of platelet blockers proves effective in phase III trial

March 26, 2012
Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in patients with known atherosclerosis, a hardening and narrowing of ...

Novel anti-platelet therapy reduces risk of cardiac events in patients with history of heart attack

August 27, 2012
According to new research from Brigham and Women's Hospital (BWH), adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular ...

Lower achieved platelet reactivity associated with better cardiovascular

August 30, 2011
Compared to patients who had persistently high platelet reactivity, those who achieved low platelet reactivity, according to the VerifyNow P2Y12 Test, had a reduced incidence of cardiovascular death, heart attack and stent ...

Antiplatelets: 1 person, 1 dose?

April 14, 2011
An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, ...

Recommended for you

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

'Fat but fit' are at increased risk of heart disease

August 14, 2017
Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

Study hints at experimental therapy for heart fibrosis

August 14, 2017
Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury—describing an experimental molecular treatment ...

Scientists identify mutations in venous valve disease

August 14, 2017
A team of scientists has discovered that mutations in the genes FOXC2 and GJC2 are associated with defects in venous valves, flaps within veins that help maintain proper blood flow.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.